Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 7/20 | 0.33 |
| ▸ | PPARA | Q07869 | 7/20 | 0.33 |
| ▸ | PPARD | Q03181 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796638 | 0.94 | TSHR (0.36) | TSHRCYP2C9PTPN11PPARGPPARA | |
| SCHEMBL22540493 | 0.91 | TSHR (0.37) | TSHRCYP2C9RAB9AALDH1A1LMNA | |
| SCHEMBL19007877 | 0.90 | TSHR (0.34) | TSHRCYP2C9PTPN11PPARGPPARA | |
| SCHEMBL19797012 | 0.88 | PPARD (0.37) | TSHRCYP2C9PTPN11PPARGPPARA | |
| SCHEMBL22606229 | 0.88 | TSHR (0.33) | TSHRCYP2C9RAB9AALDH1A1LMNA | |
| SCHEMBL22540492 | 0.88 | TSHR (0.35) | TSHRCYP2C9RAB9AALDH1A1LMNA | |
| SCHEMBL22540499 | 0.87 | TSHR (0.39) | TSHRCYP2C9RAB9AALDH1A1LMNA | |
| SCHEMBL22483576 | 0.87 | TSHR (0.32) | TSHRCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL21305334 | 0.87 | DGAT1 (0.32) | TSHRCYP2C9PPARGPPARAPPARD | |
| SCHEMBL19796517 | 0.86 | TSHR (0.38) | TSHRCYP2C9RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | DIC CORPORATION (JP) | 2023-09-19 | — | — | US | disclosed |
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | DIC CORPORATION (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20200308488-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT IN WHICH THE COMPOUND IS USED | DIC CORPORATION (JP) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | SFXN1, SFXN3, SIK3 | TSHR 2186/4885CYP2C9 1642/4885PTPN11 2707/4885 |
| US-20200308488-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT IN WHICH THE COMPOUND IS USED | SFXN1, SFXN3, SIK3 | TSHR 2186/4885CYP2C9 1642/4885PTPN11 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.